Skip to main content

Cerenis Therapeutics Holdings S (THRPF) Stock

Cerenis Therapeutics Holdings S Stock Details, Movements and Public Alerts

Stock Details

Cerenis Therapeutics Holdings S (THRPF), a prominent company in the healthcare sector within the biotechnology industry, is based in France and primarily trades on the STU.Currently, the stock is trading at $0.23. Over the past 52 weeks, it has ranged between $1.64 and $5.17. This places the current price at 4.4% of its 52-week high and -86.0% above its 52-week low. 0The 14-day Relative Strength Index (RSI) stands at 9.83, suggesting oversold conditions. The stock is currently trading below its 50-day moving average of $0.23 by 0.00%. The MACD histogram is 0.00, indicating neutral momentum (MACD Line: -0.01, Signal Line: -0.01).

52-Week Range

$5.17 - $1.64

-95.55% from high · +-85.98% from low

Avg Daily Volume

N/A

0

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

14.06

EV/EBITDA

-11.77

EPS (TTM)

-$0.16

Price to Sales

19.28

Beta

0.46

Less volatile than market

Q:How is THRPF valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is THRPF's risk profile compared to the market?
With a beta of 0.46, Cerenis Therapeutics Holdings S is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 14.06 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-136.60%

Operating Margin

-165.02%

EBITDA

$-5,423,000

Return on Equity

-92.29%

Return on Assets

-25.97%

Revenue Growth (YoY)

-11.90%

Q:How profitable and efficient is THRPF's business model?
Cerenis Therapeutics Holdings S achieves a profit margin of -136.60%, meaning it retains $-136.60 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -165.02% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -92.29% and ROA at -25.97%, the company achieves moderate returns on invested capital.
Q:What are THRPF's recent growth trends?
Cerenis Therapeutics Holdings S's revenue declined by 11.90% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$78.3M

Revenue (TTM)

$4.06M

Revenue/Share (TTM)

$0.12

Shares Outstanding

43.51M

Book Value/Share

$0.13

Asset Type

EQUITY

Q:What is THRPF's market capitalization and position?
Cerenis Therapeutics Holdings S has a market capitalization of $78.3M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 43.51M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does THRPF's price compare to its book value?
Cerenis Therapeutics Holdings S's book value per share is $0.13, while the current stock price is $0.23, resulting in a price-to-book (P/B) ratio of 1.80. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As EQUITY, this represents a specific type of security.

Fundamentals last updated: Sep 20, 2026, 02:34 AM

Technical Indicators

RSI (14-day)

9.83

Oversold

50-Day Moving Average

$0.23

0.00% below MA-50

MACD Line

-0.01

MACD Signal

-0.01

MACD Histogram

N/A

Neutral

Q:What does THRPF's RSI value tell investors?
The RSI (Relative Strength Index) for THRPF is currently 9.83, indicating the stock is in oversold territory (below 30). This indicates heavy selling pressure that may have pushed the price too low too fast. Oversold readings can present buying opportunities, but stocks can remain oversold in strong downtrends. Look for RSI to rise above 30 as a potential recovery signal. Combined with the price being below the 50-day moving average, this shows mixed signals requiring careful analysis.
Q:How should traders interpret THRPF's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.01 below the signal line at -0.01, with histogram at 0.00. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead.

Indicators last updated: Jan 11, 2026, 12:59 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for THRPF and get notified when the price changes.

Stay Ahead of the Market with Cerenis Therapeutics Holdings S Alerts

Set up price alerts for Cerenis Therapeutics Holdings S and get notified instantly when the price hits your target. Never miss an important price movement again.